CSTL PE Ratio & Valuation, Is CSTL Overvalued
This article analyzes the valuation of Castle Biosciences Inc (CSTL). It concludes that CSTL is currently in the "Fair zone" based on its forward PS ratio, with a fair price range of $23.47 to $129.73. The analysis also compares CSTL's P/S ratio to its competitors, noting that its premium, despite robust revenue growth, appears unsustainable.
Castle Biosciences CEO Maetzold sells shares worth $106,598
Castle Biosciences Inc (NASDAQ:CSTL) President and CEO Derek J. Maetzold sold 4,400 shares of common stock for $106,598 on March 26, 2026, under a pre-arranged trading plan. Despite the stock's recent decline and being undervalued according to InvestingPro, the company recently surpassed Q4 2025 earnings and revenue expectations. Analysts have maintained a Buy rating, citing strong revenue growth and positive data presented from its DecisionDx-Melanoma test.
Castle Biosciences (CSTL) CEO executes 10b5-1 share sales, exercises options
Castle Biosciences (CSTL) President and CEO Derek J. Maetzold recently exercised stock options for 550 shares and subsequently sold 4,172 common shares at a weighted-average price of $25.551, all part of a pre-planned Rule 10b5-1 trading plan. Following these transactions, Maetzold directly holds 21,479 common shares and 13,732 options, in addition to significant indirect holdings through family trusts. This activity was detailed in a recent SEC Form 4 filing, outlining both direct and indirect beneficial ownership changes.
Director at Castle Biosciences (CSTL) acquires 5,329 shares via RSUs
Rodney Cotton, a director at Castle Biosciences (CSTL), exercised 5,329 Restricted Stock Units (RSUs) on March 26, 2026, converting them into common shares at an exercise price of $0.00. This transaction increased his direct holdings of Castle Biosciences common stock to 19,331 shares. The event is classified as a routine compensation-related equity vesting and exercise, not an open-market purchase or sale.
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Castle Biosciences will present new data at the 2026 American Academy of Dermatology Annual Meeting demonstrating that its DecisionDx-Melanoma test significantly refines mortality risk prediction for patients with cutaneous melanoma within American Joint Committee on Cancer (AJCC) stages. This test helps identify patients at significantly higher or lower risk of poor outcomes than staging alone would suggest, enabling more personalized management decisions, including escalating care for higher-risk individuals and potentially reducing unnecessary interventions for lower-risk ones. The findings from 1,868 SEER-linked patients show the test's ability to stratify five-year melanoma-specific survival rates across various T categories and AJCC substages.
Castle Biosciences Study Shows DecisionDx-Melanoma Test Enhances Risk Prediction Within AJCC Staging System
Castle Biosciences announced that its DecisionDx®-Melanoma test significantly improves risk prediction for cutaneous melanoma patients within the AJCC staging system. The findings, to be presented at the American Academy of Dermatology (AAD) meeting in 2026, demonstrate the test's ability to support personalized and risk-aligned management strategies. By offering insights beyond traditional staging, the genomic test aims to enhance clinical decision-making for melanoma treatment.
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
New data from Castle Biosciences, Inc. will be presented at the 2026 American Academy of Dermatology Annual Meeting, demonstrating that its DecisionDx-Melanoma test significantly improves risk prediction within AJCC stages for patients with cutaneous melanoma. The test identifies clinically meaningful differences in mortality risk, enabling more personalized and risk-aligned management decisions. This allows clinicians to escalate care for higher-risk patients while potentially avoiding unnecessary interventions for those at lower risk, complementing traditional staging methods.
Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026
Castle Biosciences will present new data at the 2026 American Academy of Dermatology Annual Meeting, demonstrating that its DecisionDx-Melanoma test significantly improves risk prediction for cutaneous melanoma within AJCC stages. The test helps identify clinically meaningful differences in mortality risk, allowing for more personalized patient management. This allows clinicians to better stratify patients, potentially leading to more targeted care escalation for high-risk individuals and avoiding unnecessary interventions for lower-risk patients.
Derek Maetzold reports multiple Rule 144 sales — CSTL (CSTL)
Derek Maetzold has reported multiple proposed sales of Common shares for Castle Biosciences (CSTL) under Rule 144, with transactions occurring between January 5, 2026, and March 18, 2026. The SEC filing details numerous individual dispositions by Mr. Maetzold and related trusts, listing share counts and dollar values for each trade, including a 23,179-share sale on March 12, 2026. These entries are standard Rule 144 resale disclosures, documenting intended or proposed sales rather than new company actions.
Vanguard realigns reporting; holds 0% of Castle Biosciences (CSTL)
Vanguard has filed an amended Schedule 13G/A, reporting 0% beneficial ownership in Castle Biosciences (CSTL) due to an internal realignment of its subsidiaries. This change is in accordance with SEC Release No. 34-39538, allowing subsidiaries to report beneficial ownership separately. Ashley Grim, Head of Global Fund Administration, signed the filing, noting that The Vanguard Group no longer has beneficial ownership over securities held by these subsidiaries.
Q4 2025 Castle Biosciences Inc Earnings Call Transcript
Castle Biosciences Inc. reported a Q4 and full-year 2025 revenue of $344.2 million, driven by a 37% increase in test report volume and strong growth in its Tissue Cipher test. Despite a net loss of $24.2 million for the year and a decreased gross margin, the company maintained a strong balance sheet and is investing in growth initiatives, including the Advanced ADTX test. Challenges include achieving FDA approval for its Decision DX melanoma test and rising operating expenses.
Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study - Slideshow (NASDAQ:CSTL)
Castle Biosciences, Inc. (CSTL) discussed the clinical utility and evidence supporting their DecisionDx Melanoma test and the DECIDE study in a recent slideshow. The company presentation highlights key data and insights regarding their diagnostic product for melanoma. This article was published by SA Transcripts.
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Castle Biosciences, Inc. (NASDAQ:CSTL) has received a "Moderate Buy" consensus rating from ten brokerages, with an average one-year target price of $47.57. The company recently beat earnings estimates, reporting ($0.08) EPS and $81.88 million in revenue, and institutional investors hold a significant portion of its stock. Despite recent insider selling, analysts maintain a positive outlook on the biopharmaceutical company focusing on dermatologic conditions.
Maetzold, Castle Biosciences CEO, sells $500k in CSTL stock
Castle Biosciences CEO, Derek J. Maetzold, sold 19,300 shares of common stock totaling over $500,000 on March 17 and 18, 2026, pursuant to a pre-arranged trading plan. Despite these sales, the stock is considered undervalued by InvestingPro, with analysts setting price targets between $44 and $52. The company also recently exceeded Q4 2025 earnings and revenue expectations.
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 18,650 Shares of Stock
Castle Biosciences (NASDAQ:CSTL) insider Derek Maetzold sold 18,650 shares of the company's stock for approximately $483,595, reducing his stake by 45.73%. The sale occurred on Tuesday, March 17th, with shares priced at $25.93. Despite the insider selling, analysts maintain a "Moderate Buy" rating with a consensus target price of $47.57, and institutional investors hold about 92.6% of the stock.
Derek Maetzold Sells 650 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
Derek Maetzold, an insider at Castle Biosciences (NASDAQ:CSTL), sold 650 shares of the company's stock on March 18th at an average price of $25.39, reducing his stake by 2.94%. Following the transaction, Maetzold now owns 21,479 shares valued at approximately $545,351.81. The company recently reported better-than-expected quarterly earnings and revenue, and analysts currently have a "Moderate Buy" rating with an average target price of $47.57 for CSTL.
Castle Biosciences (CSTL) CEO sells 19,300 shares under 10b5-1 plan
Castle Biosciences CEO Derek J. Maetzold reported selling a total of 19,300 shares of Common Stock in open-market transactions on March 17 and March 18, 2026, at weighted-average prices around $25.93 and $25.39, respectively. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Following these transactions, Maetzold directly holds 21,479 shares and has substantial indirect holdings through various family trusts.
Castle Biosciences introduces 487-gene panel to guide JAK inhibitor or Th2 therapy decisions
Castle Biosciences has launched AdvanceAD-Tx, a new genetic testing platform that analyzes the expression of 487 genes across 12 inflammatory and cutaneous biology pathways. This platform offers clinicians either a JAK Inhibitor Responder Profile or a Th2 Molecular Profile to help personalize treatment strategies. The introduction of AdvanceAD-Tx reinforces the company's focus on precision medicine, building on previous research demonstrating the accuracy of its i31-SLNB test in melanoma diagnosis.
Castle Biosciences (NASDAQ: CSTL) CEO sells 30,779 shares under 10b5-1 plan
Castle Biosciences Inc. President and CEO Derek J. Maetzold recently sold 30,779 shares of common stock in open-market transactions on March 13 and March 16, 2026. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan established on December 3, 2025, at weighted-average prices ranging from $25.447 to $26.680 per share. Following these transactions, Maetzold directly holds 40,779 shares, with additional indirect holdings through various family and grantor retained annuity trusts.
Castle Biosciences (NASDAQ: CSTL) CCO sells 20,863 pre-planned shares
Castle Biosciences' Chief Commercial Officer, Juvenal Tobin, sold 20,863 shares of common stock at a weighted-average price of $25.24 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Following the sale, Tobin directly holds 86,825 shares of the company.
Castle Biosciences Officer Sells Shares
Juvenal Tobin W, Chief Commercial Officer of Castle Biosciences (CSTL), sold 20,863 shares of company stock on March 12, 2026, for a total of $526,582. The sale was made at a weighted average price of $25.24 per share and was executed under a Rule 10b5-1 plan established in December 2025. Following this transaction, Tobin directly holds 86,825 shares in the company.
Castle Biosciences (NASDAQ:CSTL) Insider Sells $526,582.12 in Stock
Castle Biosciences insider Tobin Juvenal sold 20,863 shares of the company's stock for over $526,000, reducing his stake by nearly 20%. This transaction follows the company's recent earnings beat, where it surpassed EPS and revenue estimates. Despite the insider sale, analysts maintain a "Moderate Buy" consensus rating for CSTL with an average target price of $47.57.
New melanoma test flags patients who can skip lymph node biopsy
Castle Biosciences' DecisionDx-Melanoma's i31-SLNB test effectively identifies melanoma patients at low risk of sentinel lymph node (SLN) positivity, allowing many to forgo SLNB procedures. A new prospective multicenter study published in Future Oncology shows that patients with less than a 5% predicted risk by i31-SLNB had an actual SLN positivity rate of only 2.6%, and demonstrated a 97.8% three-year recurrence-free survival rate. This test surpasses guidelines and other predictive gene expression profile tests, offering a more precise tool for clinical decision-making.
Castle Biosciences (CSTL) CEO sells 44,125 shares under 10b5-1 plan
Castle Biosciences President and CEO Derek J. Maetzold reported exercising stock options and selling 44,125 shares of common stock on March 11 and March 12, 2026. These transactions, which included direct and indirect holdings through trusts, were conducted under a pre-planned Rule 10b5-1 trading plan adopted in December 2025. Following these sales, Maetzold directly holds 71,558 shares, with additional indirect holdings through various trusts.
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
Castle Biosciences, Inc. announced the publication of a prospective, multi-center study in Future Oncology, confirming that their DecisionDx-Melanoma’s i31-SLNB test accurately identifies cutaneous melanoma patients who can safely forgo sentinel lymph node biopsy (SLNB). The study found that patients with a predicted risk of less than 5% for a positive SLN by i31-SLNB had a very low actual positivity rate and a high three-year recurrence-free survival. This performance significantly outperforms traditional staging criteria and other predictive gene expression profile tests, offering a more precise tool for risk-aligned patient management and reducing unnecessary procedures.
CSTL (NASDAQ: CSTL) Form 144 shows proposed resale of 20,863 shares
Castle Biosciences Inc. (NASDAQ: CSTL) has filed a Form 144 indicating a proposed resale of 20,863 shares of common stock with an aggregate market value of $528,251.16. The filing also notes a prior sale of 13,200 shares by Tobin Juvenal on December 11, 2025. This Form 144 is a regulatory notice of intent to sell and does not mean the shares have already been sold, with actual market impact depending on future transactions.
Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB
A new prospective, multicenter study published in Future Oncology validates that Castle Biosciences' DecisionDx-Melanoma's i31-SLNB test accurately identifies cutaneous melanoma patients with a low risk of sentinel lymph node (SLN) positivity, outperforming traditional staging criteria. The study found that patients predicted to have less than a 5% risk by i31-SLNB had an actual SLN positivity rate of 2.6% and a 97.8% three-year recurrence-free survival. These results support using the i31-SLNB to guide decisions on foregoing SLNB in alignment with NCCN guidelines, reducing unnecessary procedures and associated costs.
Castle Biosciences, Inc. (CSTL) reports Q4 loss, beats revenue estimates
Castle Biosciences, Inc. (CSTL) announced a Q4 loss, but exceeded revenue estimates. This suggests a mixed financial performance with sales outperforming expectations despite the reported loss.
Castle Biosciences Inc (CSTL) CFO Frank Stokes Sells 6,001 Shares
Castle Biosciences Inc (CSTL) CFO Frank Stokes sold 6,001 shares of the company on March 5, 2026, reducing his holding to 60,085 shares. This sale is part of a trend of 38 insider sells and no insider buys at the company over the past year, with Stokes having sold 22,885 shares during that period. Despite the insider selling, Castle Biosciences is considered modestly undervalued with a price-to-GF-Value ratio of 0.88, trading at $27.98 per share against a GuruFocus Value of $31.69.
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Director Sells 7,403 Shares of Stock
Castle Biosciences (NASDAQ:CSTL) Director G. Bradley Cole sold 7,403 shares of the company's stock on March 5th for a total of $210,763.41, reducing his position by over 27%. Despite this insider selling, analysts maintain a "Moderate Buy" rating for CSTL with a consensus price target of $47.57, as the company recently exceeded earnings expectations, though it remains unprofitable. Institutional investors hold a significant portion of the stock.
Insider Selling: Castle Biosciences (NASDAQ:CSTL) CFO Sells 6,001 Shares of Stock
Castle Biosciences (NASDAQ:CSTL) CFO Frank Stokes sold 6,001 shares of company stock on March 5th, totaling $167,907.98, reducing his stake by 9.08%. This follows a previous sale of 7,000 shares on March 3rd. Despite recent positive earnings and revenue, the company remains unprofitable, though analysts maintain a "Moderate Buy" rating with a consensus target price of $47.57.
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
Castle Biosciences announced new data from a large prospective multicenter study on its DecisionDx-Melanoma's i31-SLNB test. The study, presented at the SSO 2026 Annual Meeting, validates the test's ability to accurately predict sentinel lymph node (SLN) positivity, identifying low-risk patients who can safely consider forgoing SLN biopsy. For patients predicted to have less than a 5% risk of SLN positivity, the actual rate was 2.6%, aligning with NCCN guidelines that recommend avoiding SLNB below this threshold.
Frank Stokes Sells 7,000 Shares of Castle Biosciences (NASDAQ:CSTL) Stock
Frank Stokes, CFO of Castle Biosciences (NASDAQ:CSTL), sold 7,000 shares of the company's stock on March 3rd at an average price of $27.44, totaling $192,080. This transaction reduced his direct holdings by 11.77% to 52,483 shares. The company recently reported better-than-expected quarterly earnings and holds a "Moderate Buy" consensus rating from analysts.
Castle Biosciences to Present Data at SSO 2026 on
Castle Biosciences will present new data at the Society of Surgical Oncology (SSO) 2026 Annual Meeting regarding its DecisionDx-Melanoma’s i31-SLNB test. This test helps identify T1b–T2a melanoma patients who may safely avoid sentinel lymph node biopsy (SLNB) by providing a personalized risk assessment of SLN positivity. The data aims to support risk-aligned management decisions, integrating tumor biology with traditional clinical features for more precise risk estimation.
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k By Investing.com
Castle Biosciences (CSTL) Chief Financial Officer Frank Stokes sold 7,000 shares of common stock for approximately $192,073 on March 3, 2026. This sale occurred amidst recent stock volatility, though shares are up 35.6% over the past year. Concurrently, Stokes disposed of additional shares to cover tax obligations and acquired new shares through option exercises and Restricted Stock Units, while InvestingPro analysis suggests the stock is undervalued despite recent weakness.
Melanoma test may let some patients skip lymph node surgery
Castle Biosciences (Nasdaq: CSTL) will present new data at SSO 2026 on its DecisionDx-Melanoma's i31-SLNB algorithm, which can predict sentinel lymph node (SLN) positivity. This algorithm helps identify T1b–T2a melanoma patients who may safely avoid SLN biopsy, a surgical procedure. The company highlights that this integrated approach, combining a 31-gene expression profile with clinicopathologic factors, provides more precise risk estimation and supports risk-aligned patient management decisions.
Castle Biosciences to Present Data at SSO 2026 on
Castle Biosciences will present new data at the Society of Surgical Oncology (SSO) 2026 Annual Meeting regarding its DecisionDx-Melanoma’s i31-SLNB test. This test identifies T1b–T2a melanoma patients who may safely avoid sentinel lymph node biopsy (SLNB) by providing a more precise risk estimation through an integrated algorithm. The company aims to highlight how this test can guide risk-aligned management decisions, consistent with National Comprehensive Cancer Network® guidelines.
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Castle Biosciences will host a grand opening for its new corporate headquarters in Friendswood, Texas, on March 24, 2026. The new facility, designed to foster collaboration and innovation, features modern workspaces, energy-efficient systems, employee amenities, and a 23-acre wooded campus. This investment underscores Castle's commitment to its employees, patients, and the Friendswood community, supporting its continued growth as a diagnostics company.
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Castle Biosciences, Inc. is set to open its new corporate headquarters in Friendswood, Texas, on March 24, 2026. The 23-acre campus features modern workspaces, advanced technology, and employee amenities, reflecting the company's commitment to innovation and the local community. The new facility will support Castle's growth and its development of molecular tests in dermatologic and gastroenterological diseases.
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Castle Biosciences, Inc. (Nasdaq: CSTL) will celebrate the grand opening of its new corporate headquarters in Friendswood, Texas, on March 24, 2026. The new facility is designed to foster collaboration and innovation, featuring modern workspaces, advanced technology, and employee amenities like a fitness center and walking trails. This investment underscores Castle Biosciences' commitment to the region and its continued growth in providing innovative molecular tests.
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Castle Biosciences, Inc. (Nasdaq: CSTL) is set to host a grand opening for its new corporate headquarters in Friendswood, Texas, on March 24, 2026. The new facility is designed to foster collaboration and innovation, reflecting the company's commitment to its employees and the local community. It features modern workspaces, advanced technology, sustainable design elements, and employee-focused amenities to support the company's continued growth in diagnostic testing.
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
Castle Biosciences, Inc. is opening its new corporate headquarters in Friendswood, Texas, on March 24, 2026. The 23-acre campus features modern workspaces, energy-efficient systems, and employee amenities, reflecting the company's commitment to innovation, sustainability, and the local community. This expansion supports Castle Biosciences' continued growth in developing innovative molecular diagnostic tests.
Canaccord reiterates Castle Biosciences stock rating on Q4 beat
Canaccord Genuity reiterated a Buy rating and $50 price target for Castle Biosciences (NASDAQ:CSTL) after the company surpassed Q4 expectations with strong revenue growth and increased test volumes. Despite analysts not anticipating profitability this year, the company initiated 2026 revenue guidance ahead of consensus and remains optimistic about future reimbursement successes and market penetration.
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
Castle Biosciences, Inc. announced its financial results for the fourth quarter and full-year ended December 31, 2025, exceeding 2025 guidance with $344 million in revenue. The company reported a 37% increase in total test reports for DecisionDx-Melanoma and TissueCypher core revenue drivers over 2024, alongside the limited access launch of its AdvanceAD-Tx test. Despite a net loss for the year, Castle Biosciences maintained a strong balance sheet with $299.5 million in cash and offered a 2026 revenue outlook of $340-$350 million.
Castle Biosciences, Inc. (CSTL) Stock Analysis: Unveiling a Promising 50.96% Upside for Investors
Castle Biosciences, Inc. (CSTL) is presented as an intriguing investment opportunity in the healthcare sector, specifically in molecular diagnostics for dermatologic cancers. Analysts project a potential upside of 50.96%, with strong buy ratings, despite the company currently facing profitability challenges. Its innovative diagnostic solutions position it for growth in personalized medicine, making it a compelling prospect for investors interested in healthcare diagnostics.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2025 Earnings Call Transcript
Castle Biosciences (NASDAQ:CSTL) reported strong Q4 and full-year 2025 results, with total revenue of $87.0 million for Q4 and $344.2 million for the full year. The company saw significant growth in its core revenue drivers, particularly TissueCypher with 86% year-over-year growth, and launched its first-in-class AdvanceAD-Tx test. Looking ahead to 2026, Castle Biosciences anticipates total revenue between $340 million and $350 million, driven by continued momentum in its dermatologic and gastrointestinal franchises, and is pursuing FDA clearance for DecisionDx-Melanoma to leverage state biomarker laws for reimbursement.
Castle Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Castle Biosciences Inc (CSTL) has reported its financial results for the quarter that ended on December 31. This earnings summary was published by Reuters through TradingView News.
Skin cancer test maker lifts core volumes 37%, ends 2025 with $24.2M loss
Castle Biosciences reported its full-year 2025 financial results, with total revenue reaching $344.2 million, surpassing guidance. Core test volumes for DecisionDx-Melanoma and TissueCypher significantly increased by 37% year-over-year. Despite revenue growth, the company posted a net loss of $24.2 million for 2025, primarily due to non-cash stock-based compensation and a one-time amortization adjustment, and forecasts 2026 revenue between $340-$350 million.
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
Castle Biosciences reported its fourth-quarter and full-year 2025 financial results, exceeding revenue guidance with $344 million for the year. The company saw significant growth in its core revenue drivers, DecisionDx-Melanoma and TissueCypher, and announced the limited access launch of AdvanceAD-Tx™. Despite a net loss for the year, the company maintains a strong balance sheet and anticipates continued growth in 2026.
Expert Outlook: Castle Biosciences Through The Eyes Of 6 Analysts
Six analysts have provided a range of opinions on Castle Biosciences (NASDAQ: CSTL) over the past three months, with the majority being bullish. Their 12-month average price target for the stock has risen by 27.7% to $47.67, driven by recent upgrades. The company's financial performance shows a significant market capitalization and strong net margins, despite a recent decline in revenue growth.
